Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 01 Feb 2009 Results have been published in Diabetes, Obesity and Metabolism.
- 01 Feb 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism.
- 23 Dec 2008 Additional trial identifier 2005-004667-36 reported by ClinicalTrials.gov.